EN DE
Watch GKB OPHTHALMICS LTD. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GKB OPHTHALMICS LTD. (GKB) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of GKB OPHTHALMICS LTD. stock ₹53.18, price ₹63.59, that is 16.4% below the price, quality 55 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE265D01015

GO GKB OPHTHALMICS LTD. logo Thin data Nov 14, 2026

GKB OPHTHALMICS LTD.

GKB · BSE

Expensive (fair value 16% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Costs just 9.5 times its yearly profit. 
Quality 55/100 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +21.3 %/yr in INR) 
Thin margins · 2.2% net margin (TTM) 
Mixed vs. peers (5/12) 
Fair value ₹53.18 · Overvalued 
Negative free cash flow 
Narrow moat 28/100 · thin data
Thin data 
⚠ Thinly traded⚠ Small free float
Watch GKB OPHTHALMICS LTD. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹191.05 ₹47.26 Fair Value ₹53.18 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹47.26 – ₹191.05 · fair‑value band ₹39.89 – ₹66.48 · the ₹63.59 price screens above the ₹53.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow GKB OPHTHALMICS in your weekly email

Every Wednesday you see whether GKB OPHTHALMICS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

GKB Ophthalmics Limited manufactures and sells ophthalmic lenses in India and internationally. It offers finished and semi-finished glass and plastic lenses. The company was founded in 1981 and is based in Mapusa, India.

Stock analysis

GKB OPHTHALMICS LTD. (GKB) currently trades at ₹63.59, while our model-based Fair Value estimate is ₹53.18, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ₹85.49 per share, and 7 of the 15 models we run sit above the ₹63.59 price.

Bear case: the Earnings-Based group reads lowest at ₹37.16, and 8 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹39.89 (bear) to ₹66.48 (bull), the price of ₹63.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

GKB OPHTHALMICS LTD. reported revenue of ₹1.5B in FY2026 versus ₹709M in FY2022, a compound +20.4%/yr. Reported net income was ₹12.2M in FY2026, compounding −1.1%/yr from FY2022.

Key figures

Market cap ₹321M (≈ $3.4M) Micro · P/E ratio 9.9 · P/S ratio 0.21 · EPS (TTM) ₹6.43 · Net margin 2.2% · Return on equity 5.4% · Return on assets (EBIT) 0.0% (5-year average) · Operating margin 5.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −16%, GKB screens cheaper than that median.

Fair Value models

Bear ₹39.89 Fair Value ₹53.18 Bull ₹66.48
Price ₹63.59 · Downside -16.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹4.07 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹42.74 ₹77.93 ₹136.99 73
EPV ₹32.19 ₹36.52 ₹40.14 73
Residual Income ₹64.21 ₹65.54 ₹70.19 71
All 15 models by family
DCF Models
Owner Earnings ₹42.74 ₹77.93 ₹136.99 73
Earnings-Based
Graham-Dodd ₹16.44 ₹92.75 ₹128.87 63
Lynch FV ₹26.01 ₹37.16 ₹48.30 61
PEG = 1.0 ₹26.01 ₹37.16 ₹48.30 57
EPV ₹32.19 ₹36.52 ₹40.14 73
Multiples
P/E Multiple ₹39.89 ₹53.18 ₹66.48 63
P/S Multiple ₹30.82 ₹41.10 ₹51.37 57
P/B Multiple ₹58.09 ₹77.46 ₹96.82 55
EV/EBIT ₹47.62 ₹65.89 ₹84.16 65
EV/EBITDA ₹65.09 ₹89.18 ₹113.28 67
EV/Revenue ₹31.93 ₹48.70 ₹65.46 52
Asset-Based
NCAV (Graham) ₹56.42 ₹85.49 ₹106.86 54
Economic Profit
Residual Income ₹64.21 ₹65.54 ₹70.19 71
ROIC Compounder ₹32.19 ₹36.52 ₹40.14 71
Growth Earnings
Growth-Adj P/E ₹39.76 ₹56.79 ₹73.83 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 83
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 50
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
Start year 2021 (pandemic). Over 10 years: +13.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.7% vs −9.0%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 4%
Pace: the 5-year rate starts in 2021 (pandemic)

GKB screens overvalued: fair value 16% below the price. Compare with Intuitive Surgical, Inc →

Compare GKB OPHTHALMICS LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Below median
Fair Value upside −13.4% · Below median
Profitability
Return on equity (12 months) 5.4% · Below median
Return on assets 2.3% · Below median
Net margin (12 months) 5.4% · Below median
Operating margin (12 months) 5.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 2.3% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 9.9× · Cheapest 25%
P/B 0.59× · Cheapest 25%
P/S (12 months) 0.51× · Cheapest 25%
EV/EBITDA 7.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 21
FUTURE (revenue growth)12 · sector 40
PAST (return on equity)22 · sector 26
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.65 $131.27 +48% vs GKB
EssilorLuxottica Société anonyme EL €184.50 €196.22 +6% vs GKB
Intuitive Surgical, Inc ISRG $437.75 $353.90 −19% vs GKB
Medline Inc MDLN $39.17 $28.59 −27% vs GKB
Alcon Inc ALC CHF 62.14 CHF 35.08 −44% vs GKB
Becton, Dickinson and Company BDX $216.47 $97.80 −55% vs GKB
Straumann Holding STMN CHF 108.75 CHF 45.50 −58% vs GKB
West Pharmaceutical Services, Inc WST $417.80 $139.22 −67% vs GKB
Sartorius Stedim Biotech S.A DIM €225.20 €54.82 −76% vs GKB
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs GKB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GKB OPHTHALMICS LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GKB OPHTHALMICS LTD. Fair Value". https://www.fairvalue-calculator.com/stock/GKB

Frequently asked questions

Is GKB OPHTHALMICS LTD. (GKB) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹53.18 versus a price of ₹63.59, about 16% lower (overvalued).
What is the fair value of GKB?
Our model-based fair value for GKB OPHTHALMICS LTD. is ₹53.18 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹63.59.
What is the quality score of GKB?
GKB OPHTHALMICS LTD. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GKB OPHTHALMICS LTD. (GKB)?
Our model-based price target is the fair value of ₹53.18 (as of Nov 14, 2026) from 15 valuation models. Cautious scenario ₹39.89, optimistic scenario ₹66.48. It is a calculation from audited fundamentals, not an analyst target.
What is the GKB OPHTHALMICS LTD. stock forecast for 2026?
Our models put fair value at ₹53.18, about 16% lower versus a price of ₹63.59 (overvalued). Cautious scenario ₹39.89, optimistic scenario ₹66.48. The calculation is refreshed regularly with new filings.
What is the revenue of GKB OPHTHALMICS LTD. (GKB)?
GKB OPHTHALMICS LTD. reported trailing-twelve-month revenue of about ₹1.5B (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of GKB OPHTHALMICS LTD. (GKB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GKB OPHTHALMICS LTD. it is ₹53.18 per share (as of Nov 14, 2026), against a price of ₹63.59. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is GKB OPHTHALMICS LTD. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, GKB trades above its calculated fair value: price ₹63.59, fair value ₹53.18, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GKB?
No. The price is what the market pays today (₹63.59); the fair value is what the company's own numbers justify (₹53.18). For GKB OPHTHALMICS LTD. the two are ₹10.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is GKB OPHTHALMICS LTD. worth?
The market values GKB OPHTHALMICS LTD. at about ₹321M (market capitalisation, as of Nov 14, 2026). Per share that is ₹63.59; our models calculate a fair value of ₹53.18 per share.
What do the bullish and bearish scenarios say about GKB?
Our models span a range for GKB OPHTHALMICS LTD.: cautious scenario ₹39.89, base ₹53.18, optimistic ₹66.48 per share (as of Nov 14, 2026, price ₹63.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GKB?
GKB OPHTHALMICS LTD. trades at a price-to-earnings ratio of 9.9 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹53.18 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.5, EV/EBITDA 7.1.
How solid is the balance sheet of GKB OPHTHALMICS LTD. (GKB)?
Balance-sheet figures for GKB OPHTHALMICS LTD. (as of Nov 14, 2026): return on equity 5.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is GKB from its 52-week high?
GKB OPHTHALMICS LTD. trades at ₹63.59, about 15% below its 52-week high of ₹74.85 and 35% above the low of ₹47.26 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹53.18 is for.
Which stocks are comparable to GKB OPHTHALMICS LTD.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GKB OPHTHALMICS LTD. stock attractive at the current price?
The data as of Nov 14, 2026: price ₹63.59, calculated fair value ₹53.18 (−16%), Quality Score 55/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GKB calculated?
We run GKB OPHTHALMICS LTD. through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹53.18 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. GKB OPHTHALMICS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GKB OPHTHALMICS LTD. (GKB)?
The closing price on Nov 17, 2026 was ₹63.59. Our model-based fair value is ₹53.18, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GKB OPHTHALMICS LTD. right now?
Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of GKB OPHTHALMICS LTD.

How large is the market capitalisation of GKB OPHTHALMICS LTD. (GKB)?
The market capitalisation of GKB OPHTHALMICS LTD. is ₹321M (≈ $3.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GKB OPHTHALMICS LTD. (GKB)?
The price-to-sales ratio of GKB OPHTHALMICS LTD. is 0.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GKB OPHTHALMICS LTD. (GKB)?
Earnings per share at GKB OPHTHALMICS LTD. are ₹6.43 (price ÷ EPS = P/E 9.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GKB OPHTHALMICS LTD. (GKB)?
The net margin of GKB OPHTHALMICS LTD. is 2.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GKB OPHTHALMICS LTD. (GKB)?
The return on equity (ROE) of GKB OPHTHALMICS LTD. is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GKB OPHTHALMICS LTD. (GKB)?
On an EBIT basis the return on assets of GKB OPHTHALMICS LTD. is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GKB OPHTHALMICS LTD. (GKB)?
The operating margin of GKB OPHTHALMICS LTD. is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GKB OPHTHALMICS LTD. (GKB)?
Revenue at GKB OPHTHALMICS LTD. is growing 2.3% versus a year earlier (3y avg +25.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does GKB OPHTHALMICS LTD. (GKB) generate?
The free cash flow of GKB OPHTHALMICS LTD. is −₹48.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GKB OPHTHALMICS LTD. (GKB) carry?
The net debt of GKB OPHTHALMICS LTD. is ₹89.9M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GKB OPHTHALMICS LTD. in the live analysis

One click puts GKB OPHTHALMICS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.